180 related articles for article (PubMed ID: 14714898)
1. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
Butters TD; Dwek RA; Platt FM
Adv Exp Med Biol; 2003; 535():219-26. PubMed ID: 14714898
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic applications of imino sugars in lysosomal storage disorders.
Butters TD; Dwek RA; Platt FM
Curr Top Med Chem; 2003; 3(5):561-74. PubMed ID: 12570866
[TBL] [Abstract][Full Text] [Related]
3. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
Lachmann RH
Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
[TBL] [Abstract][Full Text] [Related]
4. Substrate reduction therapy for glycosphingolipid storage disorders.
Lachmann RH; Platt FM
Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
[TBL] [Abstract][Full Text] [Related]
5. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
Butters TD; Dwek RA; Platt FM
Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.
Butters TD; Mellor HR; Narita K; Dwek RA; Platt FM
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):927-45. PubMed ID: 12803927
[TBL] [Abstract][Full Text] [Related]
7. Substrate reduction therapy.
Platt FM; Jeyakumar M
Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
[TBL] [Abstract][Full Text] [Related]
8. Substrate reduction therapy of glycosphingolipid storage disorders.
Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
[TBL] [Abstract][Full Text] [Related]
9. Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement.
Pastores GM
Recent Pat CNS Drug Discov; 2006 Jan; 1(1):77-82. PubMed ID: 18221193
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal storage of oligosaccharide and glycosphingolipid in imino sugar treated cells.
Boomkamp SD; Rountree JS; Neville DC; Dwek RA; Fleet GW; Butters TD
Glycoconj J; 2010 Apr; 27(3):297-308. PubMed ID: 20186478
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
Elliot-Smith E; Speak AO; Lloyd-Evans E; Smith DA; van der Spoel AC; Jeyakumar M; Butters TD; Dwek RA; d'Azzo A; Platt FM
Mol Genet Metab; 2008 Jun; 94(2):204-11. PubMed ID: 18387328
[TBL] [Abstract][Full Text] [Related]
12. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
Andersson U; Butters TD; Dwek RA; Platt FM
Biochem Pharmacol; 2000 Apr; 59(7):821-9. PubMed ID: 10718340
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
Platt FM; Jeyakumar M; Andersson U; Priestman DA; Dwek RA; Butters TD; Cox TM; Lachmann RH; Hollak C; Aerts JM; Van Weely S; Hrebícek M; Moyses C; Gow I; Elstein D; Zimran A
J Inherit Metab Dis; 2001 Apr; 24(2):275-90. PubMed ID: 11405346
[TBL] [Abstract][Full Text] [Related]
14. Substrate reduction therapy for lysosomal storage diseases.
Cox TM
Acta Paediatr Suppl; 2005 Mar; 94(447):69-75; discussion 57. PubMed ID: 15895716
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
Andersson U; Reinkensmeier G; Butters TD; Dwek RA; Platt FM
Biochem Pharmacol; 2004 Feb; 67(4):697-705. PubMed ID: 14757169
[TBL] [Abstract][Full Text] [Related]
16. Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases.
Tifft CJ; Proia RL
Glycobiology; 2000 Dec; 10(12):1249-58. PubMed ID: 11159916
[TBL] [Abstract][Full Text] [Related]
17. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
[TBL] [Abstract][Full Text] [Related]
18. Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis.
Mellor HR; Neville DC; Harvey DJ; Platt FM; Dwek RA; Butters TD
Biochem J; 2004 Aug; 381(Pt 3):861-6. PubMed ID: 15128268
[TBL] [Abstract][Full Text] [Related]
19. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Jeyakumar M; Butters TD; Dwek RA; Platt FM
Neuropathol Appl Neurobiol; 2002 Oct; 28(5):343-57. PubMed ID: 12366816
[TBL] [Abstract][Full Text] [Related]
20. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.
Platt FM; Neises GR; Dwek RA; Butters TD
J Biol Chem; 1994 Mar; 269(11):8362-5. PubMed ID: 8132559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
